Global Wound Debridement Market - 2019-2026
|出版日||ページ情報||英文 243 Pages
|創傷デブリードマンの世界市場：将来展望 Global Wound Debridement Market - 2019-2026|
|出版日: 2019年09月19日||ページ情報: 英文 243 Pages||
Wound debridement is a process to eliminate the foreign invaders, dead tissues, and toxic substances from human wounds. Wound debridement products aid in lowering the poisonous materials that prevent the wounds from getting healed. Growing geriatric population and the presence of serious wounds are propelling the market.
The global wound debridement market size was worth $ XX billion in 2018 and is expected to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period.
The global wound debridement market is driven by the increase in aging population, rise in prevalence of diabetes and associated wounds, increasing number of burn injuries, technological advancements in products, awareness programs for wound care treatment and management, growth in obesity levels and reimbursement policies.
The rising geriatric population is expected to boost the market. Many nations are facing challenges due to the ongoing and the increasing demographic shift in age among their people. As per Department of Economic and Social Affairs Population Division of United Nations, 2017, the world's population who are 60 years old will double and those of 80 years old will triple during the next 30 years. As per WHO, the number of people of age 65 or older is expected to grow to around 1.5 billion in 2050, with most of the increase in the developing countries. Thus, the growing geriatric population, who are more prone to chronic illness, are driving the market.
The technological advancements in the products are expected to boost the market. The advanced therapies are coming into play which is expected to bolster the global wound debridement market. The introduction of a single use negative pressure therapy (NPWT), primarily in-home care settings, is gaining traction. Further, the introduction of ultrasonic devices is expected to drive the wound debridement market. Ultrasonic devices offer benefits like the capacity to differentiate between non-viable and viable tissues. These devices aid in destroying biofilms and bacteria without causing damage to blood vessels. Also, on August 13, 2019, Engineers at Heriot-Watt University developed a tiny electronic sensor that will help medics to heal the wounds by "listening" to them. The microsensor aids in monitoring the tiny, microscale changes in tissue that are taking place below the bandages. Thus, the presence of technological advancements in the products are driving the market.
The growing incidence of chronic ailment such as diabetes is fuelling the global wound debridement market. Diabetic patients are likely to suffer from wounds that do not heal quickly. This may lead to severe wound infections. With the growing number of diabetics across the globe, wound debridement is gaining importance. The International Diabetes Federation reported that by 2040, diabetes incidence is expected to reach 642.0 million. Thus, the growing incidences of diabetes are driving the market.
The presence of ongoing research activities are expected to boost the market. For instance, in December 2018, according to a new research from the McGill University Health Centre (MUHC) and McGill University showed the use of a new application, called Swift Skin and Wound, which measures accurately and charts the progression of skin wounds, could potentially have a significant impact on the clinical management and the patient outcomes. Clinicians and healthcare professionals are currently using the app at the McGill University Health Centre (MUHC) in Montreal. Also, in March 2019, according to a study, published online recently in the journal Scientific Reports by a research team at the Ohio State University, stated that the electroceutical bandages could kill the bacteria around a wound, allowing the wounds to heal faster. Thus, the growing number of research activities are driving the market.
However, the high cost of debridement products and the possible complications after undergoing the wound debridement, are hampering the market.
Complications such as bleeding, removal of healthy tissues by mechanical debridement, and chances of infection through contamination are likely to restrain the market.
By product, the global wound debridement market is segmented into gels, ointments & creams, surgical devices, medical gauzes, mechanical debridement pads, ultrasonic devices, and others.
Gels segment is expected to boost the market over the forecast period, owing to the advantages such as no inflammation, reduced bleeding, and safe removal of necrotic tissues without causing infection. Also, the presence of research activities using gels are likely to bolster the market. For instance, on October 25, 2018, by incorporating a gene-suppressing drug into an over-the-counter gel, researchers at the Albert Einstein College of Medicine and their colleagues, have reduced the healing time by half and significantly improved the healing outcomes compared to the control treatments. Thus, the added advantages of gels and the presence of research activities are driving the market.
By wound type, the global wound debridement market is segmented into venous leg ulcers, diabetic foot ulcers, pressure ulcers, surgical & traumatic wounds, burns, other wounds.
The burns segment is expected to boost the market, owing to the increasing cases of burns. As per the WHO, an estimated 180 000 deaths occur every year due to burns in low- and middle-income countries. Thus, there is a need to launch different debridement products for healing it. For instance, on April 1, 2019, Kerecis, announced the results of a new case study of Kerecis Omega3 burn product at the Burn Centre of the Queen Elizabeth Hospital Birmingham. It has found that the patients with partial-thickness burn and the donor-site wounds healed quickly, with no infection, after the treatment with the fish-skin graft. Thus, the rising number of burns leading to increasing demand for debridement products are driving the market.
The pressure ulcers segment is expected to boost the market, owing to the rising prevalence of pressure ulcers and the presence of research activities regarding the treatment. According to the Agency for Healthcare Quality and Research, pressure ulcers affect up to 2.5 million patient per year, and related costs range from $9.1 to $11.6 billion per year in the US. They are largely preventable, and 60,000 patients die as a direct result of pressure ulcers each year. For instance, in July 2019, a new randomized control trial evidence confirmed the Repose® as a gold standard for pressure ulcer prevention. In this trial, Professor Dimitri Beeckman and his team have compared the effectiveness of the Repose, static air support system versus alternating air pressure support surfaces, in a nursing home population at high risk of pressure ulcers. Also, in January 2019, Bruin Biometrics, LLC ("BBI") has been granted US FDA marketing authorization for the SEM Scanner, becoming the world's first FDA-authorised device to objectively alert the clinicians to specific anatomical areas of a patient's body at increased risk for developing a pressure ulcer. Thus, the increasing prevalence of pressure ulcers and the presence of FDA approvals are driving the market.
By end-user, the global wound debridement market is segmented into hospitals, home care, specialty clinics, and others.
The specialty clinics segment is expected to boost the market over the forecast period. For instance, according to a study published in PLOS ONE by academics in Australia and the UK on March 8, 2019, showed that the specialist clinics are the most cost-effective route for the chronic wounds with better results for the patients. Chronic wounds like diabetic foot ulcers and venous leg ulcers are often associated with long-term health conditions. They found the services to be fragmented, with care delivered by a range of healthcare professionals across the primary and secondary settings with poor coordination and communication between health care providers. They have stated that such a disconnected system leads to high costs due to increased healing times, high recurrence rates, complications requiring hospitalization and reduced quality of life for the thousands of patients affected by chronic wounds in Australia.
North America is dominating the global wound debridement market in 2018 and estimated to hold significant market size over the forecast period (2019-2026) owing to the product innovations, rise in the incidence of diabetes cases, increasing healthcare spending and the growing aging population in this region.
The increasing number of wound cases in the region are expected to boost the market. For instance, the National Institute of Health has estimated that 3% of the population of 65 years and above would have a wound at some time. An even higher rate of incidence is expected, owing to the traumatic injuries and ulcers endemic in resource-poor countries to other regions. Thus, the rising number of wounds is driving the market.
The ongoing research activities for wound management by the key players in the region is expected to boost the market. According to a study published on August 14, 2019, in the open-access journal PLOS ONE by Brennan Spiegel of Cedars-Sinai Health System and colleagues found that therapeutic virtual reality (VR) is emerging as an active, non-pharmacological treatment modality for pain, anxiety disorders, and distract patients during wound care. Thus, the presence of ongoing research activities are driving the market.
The presence of key players developing wound debridement products in the region are expected to boost the market. For instance, on March 04, 2019 Organogenesis Holdings Inc. announced that PuraPly® Antimicrobial (PuraPly AM) product has positively affected the course of healing in a variety of complex, chronic wounds that were previously unresponsive to treatment. Thus, the presence of key players launching different debridement products are driving the market.
Europe is expected to grow at a high rate in 2018 and is estimated to hold significant market size over the forecast period (2019-2026). This is owing to the rising prevalence of pressure ulcers, and the government initiatives for wound management.
The rising prevalence of pressure ulcers in the region is expected to boost the market. In the UK, recent research from the NHS Improvement showed that treating pressure ulcer costs the NHS more than £3.8m per day and around 1700- 2000 patients per month develop pressure ulcers.
In June 2018, Smith & Nephew announced that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB) on the use of PICO single use Negative Pressure Wound Therapy (sNPWT). The MIB reported the prophylactic use of the PICO as a more effective alternative to the standard surgical dressings in the prevention of surgical site complications (SSCs). According to them, this is the first and the only MIB published by the NICE on an NPWT device for preventing SSCs.
The key players operating in the global wound debridement market are B. Braun Melsungen AG, Acelity L.P. Inc., Smith & Nephew, Coloplast A/S, ConvaTec Group, Paul Hartmann, Molnlycke Health Care, Lohmann & Rauscher, Medline Industries, and Integra Lifesciences.
The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the wound debridement market globally. For instance,
In June 2019, The Malaysian Society of Wound Care Professionals (MSWCP) announced their program at the 16th Asia Pacific conference on the Diabetic Limb Problems and the 2nd Global Wound Conference 2019.
In June 2019, Molnlycke has acquired a patent application from Innovation Skane, which helped to detect the infections in the wounds. Once developed, the patent is expected to play a significant role in reducing the unnecessary use of antibiotics in wound care.
On January 25, 2019, Radiometer had a partnership with Perimed, which gave Radiometer the ability to sell Perimed's unique wound care system and give Perimed the ability to expand the reach of their product through Radiometer's strong distribution network.
On 9 July 2018, Inotec AMD Limited's NATROX® Oxygen Wound Therapy has earned the prestigious 2018 product leadership award in chronic wound care management from Frost & Sullivan.
On November 27, 2018 Researchers from MedStar Washington Hospital Center and the MedStar Health Research Institute started an Investigational Device Exemption (IDE) trial on full-thickness burn wounds using Kerecis Omega3 Burn.
The Global Wound Debridement Market report would provide access to an approx, 73 market data tables, 75 figures, and 220 pages
LIST NOT EXHAUSTIVE